India’s biotechnology story is moving beyond laboratories and specialised applications, increasingly becoming an industrial story shaped by productivity, resource efficiency, sustainability and the economics of manufacturing. The scale of this transition is already visible: India’s bioeconomy grew from around $10 billion in 2014 to $165.7 billion in 2024 and reached an estimated $195.3 billion in 2025, while the national ambition is to take it to $300 billion by 2030. This growth matters to process industries because biotechnology is increasingly moving from being an enabling input to becoming a tool for improving the performance of industrial systems.
Maximising Value from Existing Capacity
Across biological conversion industries, growth is increasingly shifting from capacity expansion to extracting greater value from existing assets. India’s ethanol sector reflects this transition: production capacity has grown nearly fivefold, from 421 crore litres in 2014 to about 2,000 crore litres in 2026, while blending rose from less than 1.5% in 2013–14 to 20% in 2025–26. The shift has also created an additional route for sugarcane and other feedstocks, helping manage surplus sugar, improve mill liquidity and support more timely payments to farmers. At the same time, greater use of domestically produced ethanol can reduce crude-oil import dependence, conserve foreign exchange and strengthen India’s energy security. Importantly, biotechnology extends well beyond pharmaceuticals: India’s 2025 bioeconomy comprised BioIndustrial, BioPharma, BioServices and BioAgri, with BioIndustrial contributing $90.2 billion (46%) through industrial biotechnology, biofuels, fermented food ingredients, nutraceuticals and other bio-based applications.
Its industrial relevance lies in improving conversion, recovery, resource efficiency, productivity and value creation across fuels, food, agriculture, chemicals, materials and process industries. With E20 established, the focus is shifting towards improving fermentation, conversion, recovery and raw-material utilisation. In grain-based ethanol, starch is converted into fermentable sugars and then fermented into ethanol, making feedstock quality, process conditions and plant configuration important to yield and economics. Improvements in conversion, process control and recovery can therefore deliver meaningful gains at scale. The value of biotechnology extends beyond what an enzyme delivers in isolation; its impact lies in consistently improving productivity, efficiency and value creation across the process.
Biotechnology Across the Industrial Value Chain
This transition is also expanding into newer areas of the bioeconomy, with India’s CBG ecosystem moving towards greater scale. The recently approved GOBARdhan National Circular Bioenergy Scheme carries an outlay of ₹23,731 crore and aims to drive nearly ten-fold growth in domestic CBG production through assured offtake, pricing support, capital assistance, financing and infrastructure. As the ecosystem expands, biological conversion will need to handle diverse feedstocks while maintaining consistency, process stability and resource recovery. Similar opportunities exist across brewing, malt and spirits, where fermentation biology intersects with yield, quality and consistency. As premiumisation grows, process efficiency must also preserve product character.
This broader movement is also reflected in policy. India’s BioE3 framework specifically identifies bio-based chemicals, biopolymers, APIs and enzymes among its high-performance biomanufacturing priorities, alongside areas such as carbon capture and utilisation. The direction is clear: biotechnology is increasingly being connected to manufacturing, scale-up and commercial outcomes, creating opportunities for biological technologies to move beyond specialised applications and contribute directly to industrial productivity, efficiency, resource utilisation and value creation across India’s evolving bioeconomy.
Technology and Strategic Partnerships
For industrial operators, the growing role of biotechnology also changes how technology should be evaluated. An enzyme, for instance, should not be viewed simply as another process input judged by its purchase price or dosage, but by its cost impact against the value it creates through higher recovery, better conversion, improved productivity, reduced losses, greater consistency or more effective resource utilisation. Industrial challenges rarely exist in isolation; raw materials vary, process conditions change and every plant has its own operating realities. A meaningful technology partnership therefore requires more than supplying an enzyme or biological solution. It requires understanding the process, identifying the underlying constraint, validating the economics and supporting implementation at the plant level.
The future of biotech in India’s process industries will increasingly be shaped by the intersection of biology, engineering, implementation and economics. Across sugar processing, grain fermentation, distillation, fermentation, CBG, brewing, malt and spirits, the opportunity lies in applying technologies adapted to specific process conditions and translating them into measurable improvements in plant performance. A meaningful biotech partner therefore needs to go beyond technology supply—understanding individual plant challenges, customising solutions to operating conditions and supporting effective implementation to improve productivity, efficiency and resource utilisation.
This is the approach reflected in The Catalyst Group, where technology is complemented by process understanding, application support and implementation tailored to client requirements. Ultimately, the value of biotechnology lies not only in the technology itself, but in how effectively it is applied at the plant level. Choosing the right partner is therefore as important as choosing the right technology.
